Monday, 30th September

13th Annual Biotech in EuropeInvestor Forum

8.00

8.20

Registration & Coffee

Welcome Speech

Chaired By:Stephanie Léouzon, Principal and Head of Torreya Partners EuropePanellists:Stefan Weber, CEO, NEWRON PHARMACEUTICALS SPAStephane Boissel, Executive Vice President and CFO, Transgene S.A.David Pinniger, Fund Manager, Polar CapitalPeter Llewellyn-Davies, CFO, Medigene AG

8.30 Public Markets and M&A Panel

Chaired By:Genghis Lloyd-Harris, Partner, Abingworth LLPPanellists:Markus Hosang, General Partner, BioMedPartners AGCarole Nuechterlein, Head Roche Venture Fund, F. Hoffman-La Roche AG Roche Venture FundDeborah Harland, VP and Partner, SR One, LimitedEric Halioua,Co-Founder and CEO, Promethera BiosciencesGraeme Martin, President and CEO, Takeda Research Investment, Inc.

Investment Panel9.15

10.15 Coffee Break

Co-Chaired By:Esteban Pombo-Villar, COO, Oxford BioTherapeuticsKatya Smirnyagina, Partner, Capricorn Venture PartnersPanellists:Keith Blundy, CEO, Cancer Research TechnologyAnja König, Managing Director, Novartis Venture FundStefanos Theoharis, CBO, apceth GmbH & Co. KGWillem van Weperen, CEO, to-BBB technologies BV

10.30 Oncology NeurosciencePanorama A Panorama B

Chaired By:Chris Maggos, Business Development, Alpine Institute for DrugDiscoveryPanellists:Tom Kronbach, CEO, BioCreaDirk Beher, CSO, Asceneuron SAJuhani Lahdenperä, CEO, Hermo Pharma OY LtdMalcom Weir, Co-Founder and CEO, Heptares Therapeutics Ltd

Hamza Suria, President & CEO, AnaptysBio, Inc.Pierre-Olivier Goineau, EVP & COO, Erytech Pharma ASDr Bernd Muehlenweg, CBO, NanobiotixMark Bleckmann,Director & Head of Finance,immatics biotechnologies GmbHVladimir Cmiljanovic, CEO, PIQUR Therapeutics AGElena Startseva, Head of Business Development, OCT Clinical Trials

11.20 Platform Technologies 1

Panorama BCo-Chaired By:Christina Takke, Partner, Forbion Capital PartnersHeinz Schwer, Senior Director, MorphoSys AGPanellists:Douglas M. Fambrough, CEO, Dicerna Pharmaceuticals, Inc.Tim Knotnerus, Business Development, AM-PharmaCarlos Buesa, CEO, OryzonDavid Urech, Co-CEO and CSO, Numab AGBart Wuurman, CEO, Lanthio Pharma B.V.

Co-Chaired By:Christina Takke, Partner, Forbion Capital PartnersHeinz Schwer, Senior Director, MorphoSys AGPanellists:Thomas Jung, CMO, Delenex Therapeutics AGVincent Charlon, CEO, AnergisDr Philippe Calais, CEO, Antisense Pharma GmbHEric Massou, CFO, Poxel

Chaired By:Peter Burkhardt, CEO, EVA-the Basel life sciences start-up agencyPanellists:Bernd Goergen, Senior Investment Manager, High-Tech Gründenfonds Management GmbHJesús Martin-Garcia, General Partner, Eclosion2Nanna Lüneborg, Investment Director, Novo Seeds, Novo A/S

Panorama A Panorama B Berne

12.10 Platform Technologies 2 Emerging Company PanelDiagnostics

Chaired By:Dr Rainer Strohmenger, General Partner,Wellington PartnersPanellists:Rudi Pauwels, Executive Chairman and CEO,BiocartisJohn Clarkson, CEO, Atlas Genetics LtdOliver Schacht, CEO, Curetis AGAndré Rosenthal, CEO, Signature Diagnostics aGThomas Taapken, CEO and CFO, Epigenomics AG

Beth Jacobs, Managing Partner, Excellentia Global Partners

Men’s health, treatment of low testosterone, phase IIWomen’s health, endometriosis and breast cancer, preclinical

Biologics, immunogenicity assessment & re-engineering, ADCs (oncology)

Diagnostics, OncologyProduct Development

Cancer, molecular diagnostics, DNA methylation, marketed products

Auto-immune diseases / oral biologicals clinical phase I/II

Ophthalmology, Uveitis, Conjunctivitis, small molecule, pre-clinical

TBA Cancer, Acute Leukemia, Phase III Development of therapies to mitigate scar formation and accelerate wound healing

Molecular Diagnostics; Infectious Diseases; Personalized Medicine

Novel Ab platform, immunotherapy, in!ammation, muscle wasting, "brosis

Cancer, Platform technology for drug delivery, siRNA based therapeutics, preparing Clinical Phase I

POC molecular diagnostics. Infectious disease. Integrated, rapid, high multiplex platform

Ocular Diseases, Mucus Penetrating Particles (MPPs), Phase II/III ready

Cancer, Regenerative Medicine, Cell Therapeutics, Clinical Phase I / II

Cancer, Therapeutic vaccines, Adjuvant platform, Clinical stage I/II

Cancer Molecular Diagnostics for Breast and Gynecologic Cancers

Phase I-IV clinical trials organization and conduct in Russia and CEE

de"ned cell culture supplements, media and kits TBA Orphan Diseases, Misfolding Protein, Small Molecule, Pre-clinical

TBA Immunology, regenerative medicine, clinical phase I/II

Microbiome, biomarkers, drugs, IBD, metabolic diseases

Monday, 30th September

13th Annual Biotech in EuropeInvestor Forum

18.15 Networking Reception

Coffee Break16.00

Delenex Therapeutics AG BioCrea14.00 NEWRON PHARMACEUTICALS (NWRN:SIX)

CNS disorders, rare diseases, "ling of lead compound in US and EU

Dermatology, Biologics, Clinical Phase II Autoimmunity, Biologics, Clinical Phase I/II

First-in-class, Neurology, PsychiatryDrug Discovery, preclinical

Specialty Pharma Company focussed on anaesthesia Cancer, RNAi for undruggable targets, entering phase I

Neurology, Psychiatry, Type 2 diabetes

Paion AG (PA8:XETRA)

Ophthalmology, CNS & cancer | gene therapy development & manufacturing | Clinical Phase I/II

Cancer, immunotherapy, antisense/DNA Therapeutics, Preclinical, Phase I/II

CNS, Parkinson´s Disease, Pre-Clinical POC complete

Binosto – osteoporosis; launched. PCOS - pre–clinical. Diabetes and HCV - pre–clinical

ULTRA-FAST ALLERGY DESENSITIZATION, CLINICAL PHASE II/III

Alzheimer’s disease and tauopathies, Small Molecules, Pre-clinical

Oncology & Renal/Metabolic diseases with 3 Phase-II drugs

Acute Kidney Injury, Biological, Phase I. Ulcerative Colitis, Biological, pre-clinical

Alzheimer, Small Molecules, clinical Phase I/II

Cancer; Multi-peptide vaccines; Clinical and pre-clinical development

Cancer, Epigenetics, Small Molecule inhibitors, Clinical Phase I / II

Venue Occlusive Disease (VOD), orphan drug, de"brotide, clinical Phase II/III

Vaccines, Cytomegalovirus Infection, Solid Organ Transplantation, Clinical Phase I/II

Autoimmune diseases, bi-speci"c antibody fragment, preclinical

Drug Delivery, Micro Particle-Based Controlled Release Depot Forms

Cancer, nanomedicine, clinical phase I/II Cancer, small molecules, clinical Phase I Cancer, Small Molecules, Protein-Protein Interactions, Pre-clinical

Dicerna Pharmaceuticals, Inc Heptares Therapeutics14.15

Oxford Biomedica plc (OXB:LSE) Antisense Pharma GmbH Hermo Pharma Ltd14.30

EffRx Pharmaceuticals SA Anergis Asceneuron SA14.45

NOXXON Pharma AG AM-Pharma Probiodrug AG15.00

immatics biotechnologies GmbH ORYZON Gentium S.p.A. (GENT:NASDAQ)15.15

CAP-CMV GmbH Numab AG ALRISE Biosystems GmbH15.30

Nanobiotix (NANO:EN) PIQUR Therapeutics AG Priaxon AG15.45

Forendo Pharma Ltd PolyTherics Ltd. Medlumics S.L.16.15

Epigenomics AG (ECX:XETRA) ActoGenix NV Panoptes Pharma16.30

Biocartis ERYTECH Pharma SA (ERYP:EN) SironRx Therapeutics, Inc.16.45

Curetis AG AnaptysBio, Inc. Soluventis17.00

Atlas Genetics Ltd. Kala Pharmaceuticals apceth GmbH & Co. KG17.15

PCI Biotech (PCIB:OSLO) Provista Diagnostics, Inc. OCT Clinical Trials17.30

InFlectis BioScienceSignature Diagnostics aG17.45

Company Track A Company Track B Company Track CPanorama A Panorama B BerneChaired by Tomas Kahn Chaired by Veronica Sellar Chaired by Peter Kalinka

Company Track D Company Track E Company Track FPanorama A Panorama B BerneChaired by Lorenza Castellon Chaired by Hans Herklots Chaired by Jorgen Thorball

13.00 Networking Lunch

TNC Bio BV

18.00 AIDD Cell2B ENTEROME

SOM Biotech GeneFirst Ltd12.45

13.00 Networking Lunch

Bioxodes

Specialised pain / Neuropathic pain / Small molecules

Neuropathic Pain, Small Molecules, Late Preclinical, Expected Clinical Start in 2014 Clinical Phase I / II

Cancer, fusion proteins, Phase IIa, GBM, targeting IL-4R

Cancer , NK-cell therapy, Clinical Phase I/II Inner ear diseases, small molecules modula-tors, late pre-clinical stage

Lifestyle behavioural change clinical study

Phase II clinical trials in treatments for asthma, chronic bronchitis and lupus

Neuropathic pain. Small molecule. Phase Iib TBA

text text text

Biomarker/diagnostic antibody discoveryDrug pro!ling and mode of action studies

Regenerative medicine/ Transplantation Cardiovascular disease, Antibody Therapy, Phase I

Liver based inborn errors of metabolism, stem cell, clinical phase I/II

Cancer, screening test, market entry Recombinant Spider Silk Biomaterial for Regenerative Medicine and Wound Care

Nuclear Receptors, Small Molecules, Clinical Phase I/II Drug discovery, Virtual screening, Big data, ADME/Tox predictions 

Allergic airway diseases, whole bacteria, advanced preclinical

Diabetes, Small Molecules, Clinical Phase I / II Protein biomarkers, diagnostics, precision/personalized medicine

Molecular immune diagnostics, immunotherapy, cancer, clinical trials

Orphan, clinical stage. cancer, auto-immune diseases, advanced clinical trials

Immune mediated in#ammatory diseases, Antisense, Pre-clinical

Biopharmaceuticals, development services, clinical supply

Infectious disease, Vaccines/Immune therapies, Biologics, Pre-clinical

Fibrosis, Small Molecule inhibitors, Pre-clinical

Orphan Diseases, Repurposing, Clinical Phase II Cardiovascular disease, peptides, pre-clinical Molecular Diagnostics

Minimally Invasive Spine Surgery, Commercial Stage.

Drugs in oncology, virologoy, CNS, autoimmune. First launches in 2014

Metabolic, Small Molecules, NCE, Clinical Phase Iib. SCD1 Partial inhibitor

Biomarker, Drug Repurposing, NGS analysis

Cardiac Shunt Detection & Liver Function Assessment

Sepsis, Acute Kidney Injury, modulating antibodies, advanced preclinical

Trifunctional Antibodies in Cancer Therapy

Oral In#ammation, Small Molecules,Late Stage

Tuesday, 1st October

13th Annual Biotech in EuropeInvestor Forum

Esteve Algiax Pharmaceuticals GmbH Medicenna Therapeutics, Inc10.30

Glycostem Therapeutics Sensorion dacadoo ag10.45

Metys pharmaceuticals TBC11.00

Activiomics Ltd

Invion Limited (IVX:ASX)

t-Cell Europe GmbH Athera Biotechnologies AB11.15

Promethera Biosciences Diagnoplex SA Spiber Technologies AB11.30

Phenex Pharmaceuticals AG eADMET GmbH Protectimmun GmbH11.45

POXEL BioScale, Inc ImmunID12.00

Wilson Therapeutics BioLineRx Ltd. (BLRX:TEL AVIV) ugichem GmbH12.15

Biotechpharma Galecto Biotech12.30

8.00

8.20

Registration & Coffee

Co-Chaired By:Dr. Fintan Walton, CEO, PharmaVentures LtdChris Britten, Head, Business Development, Sanofi Pasteur MSD Panellists:Dr Frank Grams, VP, Head of R&D Alliance Management and Transactions, SanofiCorinne Savill, Head of Business Development and Licensing, Novartis Pharma AGSarah Holland, Global Head of Strategic Partnering, F. Hoffmann-La Roche Ltd.

8.30 Partnering Panel 1

Co-Chaired By:Dr. Fintan Walton, CEO , PharmaVentures LtdWilder Fulford, Partner, Torreya PartnersPanellists:Manfred Horst, Director Business Development, Merck & Co. / MSDJonathan Garen, Assistant Vice President BusinessDevelopment, Forest Laboratories, Inc.Jaume Masana, Licensing & Strategic Partnering Director, EsteveJudith Hills, Senior Vice President, Corporate Business Development, Ipsen Biopharm Limited

NLT SPINE

Galmed Pharmaceuticals Ltd.

Cardiox Corporation

Trion Pharma GmbH

Hybrid Fusion Medicals AG

BioVariance GmbH

Adrenomed AG

Zarzatech Europe Sarl

Partnering Panel 29.20

9.20

9.35

9.50

10.05

Company Track G Company Track HPanorama B BerneChaired by: Hans Herklots Chaired by Chris Maggos

Company Track I Company Track J Company Track KPanorama A Panorama B BerneChaired by Lorenza Castellon Chaired by Peter Kalinka Chaired Jorgen Thorball

10.20 Coffee Break

Origimm

End of Conference & End of Partnering

Tuesday, 1st October

13th Annual Biotech in EuropeInvestor Forum

16.00

A series od snaphot persperctivesCo-Chaired By:Edward D. Blair, Managing Director, Integrated Medicines LtdLorenza Castellon, Consultant

With an introduction by:Martina Kaufmann, Managing Director,Martina Kaufmann Strategic Consulting“Personalized Medicine - Translating promise into practise”

Speakers:Rainer Metzger, VP Global Business Development Pharma, QIAGENMagali Gibou, Senior Regulatory Affairs Manager, Transgene S.A.Seong Chen, Project Leader, Strategic Initiatives, F. Hoffmann-La RocheAlain Huriez, Venture Partner at Advent Venture Partners, and Chairman at EPEMEDHartmut Ruetten, Head Translational Medicine Diabetes R&TM, Sanofi

14.00 Personalised Medicine and Companion Diagnostics Workshop